Camrelizumab Antibody

SKU: orb1692808

Description

Camrelizumab (SHR-1210) is a high-affinity human IgG4-κ anti-PD-1 monoclonal antibody with a 3 nM binding affinity and 0.70 nM IC50 for PD-1/PD-L1 blockade. It demonstrates anti-tumor efficacy and tolerability in research models of cancers like NSCLC, ESCC, and HCC, supporting its investigation in immuno-oncology research.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 1798286-48-2
• MW: 143.7 kDa
• Purity: 98.60%
• Target: PD-1/PD-L1

Bioactivity

• Target IC50:
  PD-1/PD-L1:0.70 nM (IC50)
• In Vivo:
  Camrelizumab (3 mg/kg) administered in combination with apatinib (200 and 100 mg/kg) demonstrated tumor inhibition rates of 63.1% and 87.3%, respectively, in human PD-1 transgenic mice.
• In Vitro:
  In a T cell proliferation assay using tuberculin treated peripheral blood mononuclear cells, Camrelizumab induces a T cell proliferation at an EC50 of 0.11 nM. In a similar assay measuring IFN-gamma secretion, Camrelizumab induces IFN-gamma production at an EC50 of 0.38 nM.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PD1, PD-1, PD1/PDL1, PD-1/PD-L1, anti-PD-1, Camrelizumab, Camrelizumab(anti-PD-1), PDL1, PD-L1, SHR-1210, SHR 1210, SHR1210

Quick Database Links

Gene Symbol

PD-1/PD-L1